Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. - Wikidata - awgldk - TriplyDB

Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid.

Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid.

http://www.wikidata.org/entity/Q46570802

about

Bisphosphonates and other bone agents for breast cancer Bisphosphonates in the treatment of patients with lung cancer and metastatic bone disease: a systematic review and meta-analysis The Present and Future of Biomarkers in Prostate Cancer: Proteomics, Genomics, and Immunology Advancements Diagnosis and treatment of bone metastasis: comprehensive guideline of the Japanese Society of Medical Oncology, Japanese Orthopedic Association, Japanese Urological Association, and Japanese Society for Radiation Oncology Bone-targeted therapy in metastatic breast cancer - all well-established knowledge?Samarium for osteoblastic bone metastases and osteosarcoma Cancer treatment-related bone disease.BMP7: a new bone metastases prevention?Molecular mechanisms and treatment of bone metastasis.Natural history of malignant bone disease in breast cancer and the use of cumulative mean functions to measure skeletal morbidity.Repeatability of quantitative parameters of 18F-fluoride PET/CT and biochemical tumour and specific bone remodelling markers in prostate cancer bone metastases Bone metastases: Causes, consequences and therapeutic opportunities Comparison of the efficacy and safety of denosumab versus bisphosphonates in breast cancer and bone metastases treatment: A meta-analysis of randomized controlled trials.Zoledronic acid effectiveness against breast cancer metastases - a role for estrogen in the microenvironment?Targeted treatments of bone metastases in patients with lung cancer Risk factors for bone metastasis in patients with primary lung cancer: study protocol for a systematic review.Evolving role of bone biomarkers in castration-resistant prostate cancer.Prognostic and predictive value of clinical and biochemical factors in breast cancer patients with bone metastases receiving "metronomic" zoledronic acid.Effects of de-escalated bisphosphonate therapy on bone turnover biomarkers in breast cancer patients with bone metastases.Denosumab in patients with cancer and skeletal metastases: a systematic review and meta-analysis.Consequences of daily administered parathyroid hormone on myeloma growth, bone disease, and molecular profiling of whole myelomatous bone.Integrins and bone metastasis: integrating tumor cell and stromal cell interactions.Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer The science and practice of bone health in oncology: managing bone loss and metastasis in patients with solid tumors Docetaxel and epirubicin compared with docetaxel and prednisone in advanced castrate-resistant prostate cancer: a randomised phase II study.Renal cell carcinoma bone metastases: clinical advances Bone markers and their prognostic value in metastatic bone disease: clinical evidence and future directions.Tumor-derived syndecan-1 mediates distal cross-talk with bone that enhances osteoclastogenesis.Bone disease in multiple myeloma and precursor disease: novel diagnostic approaches and implications on clinical management.Bone remodeling markers and bone metastases: From cancer research to clinical implications Prevention and Treatment of Bone Metastases in Breast Cancer Predictors of survival in prostate cancer patients with bone metastasis and extremely high prostate-specific antigen levels Use of urinary markers in cancer setting: A literature review Bone-modifying agents in the treatment of bone metastases in patients with advanced genitourinary malignancies: a focus on zoledronic acid.Urinary N telopeptide levels in predicting the anti-nociceptive responses of zoledronic acid and paclitaxel in a rat model of bone metastases.Biochemical markers of bone turnover in patients with spinal metastases after resistance training under radiotherapy--a randomized trial.Bisphosphonates in breast cancer.Once-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer.Comparing the results of bisphosphonate use in clinical trials with actual practice: a case of apples and oranges?Treatment-induced bone loss and fractures in cancer patients undergoing hormone ablation therapy: efficacy and safety of denosumab.

P2860

Q24203656-C6D8E1F0-5584-4DE3-96DB-826817936B1C Q24608900-7C1DD26B-2802-4135-8946-EAB85A7AC435 Q26750672-027D23ED-96F7-45F0-A252-A47449D2EC51 Q28076646-C50D9187-1B22-4B07-8406-D64BE09F8EBC Q28087676-6FD38E0D-4773-4E72-8F23-E1CA7C22CD35 Q28253337-582E0FBE-B1F6-43E9-9BF2-DEB2C7A9A49A Q30438185-FBF23107-6F9E-4804-BC9E-2D9208361318 Q30443506-417D1294-7A48-446E-B396-379FC6010157 Q30445717-5962556F-3227-49A1-9F49-12E34EC03858 Q33491284-1E39776A-B648-46D4-BCE3-8FB072B760C1 Q33689314-B4CCF7A6-238E-4001-BBD0-33A176089B5C Q33697331-2970609B-90A4-4500-8A81-FA19C2620D5C Q33727640-A1C80442-10B0-45AF-A0BA-7275C85D70ED Q33739204-32F88648-54FD-4EC0-9F3E-68ED4EBB82D2 Q33759713-6B2A632A-C457-4190-A2C9-47009EA6D1D8 Q33996458-62A8D8AA-0F75-43CC-B63F-A37D6C150A38 Q34023877-2E823A79-4AA4-4EEF-B148-4B4195588326 Q34026943-14AE1115-C0C6-42FC-8FAE-17D9321E5031 Q34325491-FF8B11BE-F215-4F84-A68A-8583998F2858 Q34381979-DE15C3D7-5CFB-403A-B330-50D7BC8F3C0F Q34418934-782E7B78-40BD-4583-99CC-3A4C50293C8F Q34441622-899A7D81-55F2-48BD-894C-239D25306267 Q34613941-169D314B-3D67-4EE7-97C7-55BCD02065C8 Q34617864-59652B3F-3158-419A-8700-CB14B885C10A Q34627984-79577B6D-C86A-47EC-8248-42BE45841505 Q34631216-0F508C3B-6F63-4BCB-8A87-03B0210C9E86 Q34960867-510240CC-EA3A-46BC-B162-6B8B4DBA67E3 Q35140763-C06516FA-012C-47CD-91DA-E65E270EC649 Q35422468-C57DB133-60F4-4516-A30B-84A9A90475CC Q35531006-C04ACD52-9E70-4F4C-A384-EC51092E70B7 Q35750652-3475B2A0-80A6-42E5-BE32-2CB63C8FC1AA Q35827731-FFA3EACF-C93E-4DC5-AE42-77F0F030B207 Q35844765-6131749B-C100-446C-B64E-B80E7EEF233C Q35865726-5E874285-FF8C-4638-80F1-A995DF3066BE Q35919801-BECF97CC-C3AA-450B-BAE3-F8EAEFD418CD Q35959956-B5D81F38-2E69-4A25-93C9-479304CB94D9 Q36085307-65D1A256-D205-4FD9-8581-C67B332CFF86 Q36087899-B3B7D405-3A49-4A77-908D-EF7973D47F95 Q36089078-787F40D0-702F-416B-ABBA-0EA0CAD876ED Q36187103-69978B8F-F2DA-482E-A9B6-6BD67C119C12

P2860

Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid.

http://www.wikidata.org/entity/Q46570802

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh-hant

name

Predictive value of bone resor ...... isphosphonate zoledronic acid.

@en

Predictive value of bone resor ...... isphosphonate zoledronic acid.

@nl

type

label

Predictive value of bone resor ...... isphosphonate zoledronic acid.

@en

Predictive value of bone resor ...... isphosphonate zoledronic acid.

@nl

prefLabel

Predictive value of bone resor ...... isphosphonate zoledronic acid.

@en

Predictive value of bone resor ...... isphosphonate zoledronic acid.

@nl

P1433

Q46570802-EF8DF882-65F9-4A19-9378-C24F291848BA

P1476

Q46570802-183D428B-B271-4041-A7A4-5D4E8CBE322B

P2093

Q46570802-0ED89E5F-00F3-45FC-9973-3CEF21243CF3

Q46570802-16FBAF42-3638-40DD-B2E6-599A40DD057A

Q46570802-39F2D32F-71D2-4097-9284-9CB3704FF25D

Q46570802-59382FE6-C727-4C11-B102-E7A3BF297B4B

Q46570802-6AB113D4-89EC-42EC-B7F8-791301E6F575

Q46570802-73B7061B-D915-4B05-B98E-4F6DE1A017F3

Q46570802-8657E903-2DC2-43F6-83E3-3007A76D92DB

Q46570802-96580537-A170-4FAC-AECC-DC18D1CDE8A0

Q46570802-A539A252-D358-4282-8A77-14497262920D

Q46570802-DF82E964-6CC2-43EA-ACFB-6275E13897FD

P304

Q46570802-96395FBB-4615-4630-975C-CBB2E85B948A

P31

Q46570802-BED8D31E-FA42-4A75-A285-3A14A3ED25DD

P356

Q46570802-99E43522-5B4A-49E8-99A7-BB830BF07D84

P407

Q46570802-CD5D1EF8-F9FB-4807-A172-31CA676735E6

P433

Q46570802-C02A5C43-3CA7-41F9-9810-4AD0C5F9C0A3

P478

Q46570802-E65A32E5-B3DF-4A72-8523-905D0DA85952

P577

Q46570802-DB01D6A6-1791-4826-BBC1-B200EFFB9A0B

P698

Q46570802-F5573ACE-36C7-4C0A-8889-CCCA0C4E4A0F

P921

Q46570802-813261C9-8E71-4E85-9DC0-AB0BC6C96761

P356

JCO.2005.06.091

P1433

Journal of Clinical Oncology

P1476

Predictive value of bone resor ...... isphosphonate zoledronic acid.

@en

P2093

Allan Lipton

http://www.w3.org/2001/XMLSchema#string

Fred Saad

http://www.w3.org/2001/XMLSchema#string

Janet E Brown

http://www.w3.org/2001/XMLSchema#string

John Seaman

http://www.w3.org/2001/XMLSchema#string

Ker-Ai Lee

http://www.w3.org/2001/XMLSchema#string

Matthew Smith

http://www.w3.org/2001/XMLSchema#string

Ming Zheng

http://www.w3.org/2001/XMLSchema#string

Pierre Major

http://www.w3.org/2001/XMLSchema#string

Richard Cook

http://www.w3.org/2001/XMLSchema#string

Robert E Coleman

http://www.w3.org/2001/XMLSchema#string

P304

4925-4935

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2005.06.091

http://www.w3.org/2001/XMLSchema#string

P407

P433

22

http://www.w3.org/2001/XMLSchema#string

P478

23

http://www.w3.org/2001/XMLSchema#string

P577

2005-06-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15983391

http://www.w3.org/2001/XMLSchema#string

P921